Presented By Alan Venook at 2014 ASCO Annual Meeting
36
<br />CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum <br /> Presented By Alan Venook at 2014 ASCO Annual Meeting
description
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum . Presented By Alan Venook at 2014 ASCO Annual Meeting. Slide 2. - PowerPoint PPT Presentation
Transcript of Presented By Alan Venook at 2014 ASCO Annual Meeting
<br />CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum <br />
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 2
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: <br /> FINAL DESIGN
Presented By Alan Venook at 2014 ASCO Annual Meeting
COLORECTAL CANCER IN 2004 <br /> IS THERE AN OPTIMAL 1ST LINE TREATMENT ?
Presented By Alan Venook at 2014 ASCO Annual Meeting
2004: A lot can happen in 10 years
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB / SWOG 80405: <br /> WHY DID IT TAKE TEN YEARS?
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Eligibility Criteria
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Endpoints
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Statistics
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Statistics
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 11
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 12
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Overall Survival <br />
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Progression-Free Survival<br />(Investigator Determined)
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 15
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Overall Survival<br />FOLFOX Treated
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Overall Survival<br />FOLFIRI Treated
Presented By Alan Venook at 2014 ASCO Annual Meeting
Patients Rendered Disease-Free<br />Overall Survival
Presented By Alan Venook at 2014 ASCO Annual Meeting
Grade 3-4 Toxicities<br />
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 20
Presented By Alan Venook at 2014 ASCO Annual Meeting
80405: Data Pending
Presented By Alan Venook at 2014 ASCO Annual Meeting
Quality of Life and Symptoms
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 23
Presented By Alan Venook at 2014 ASCO Annual Meeting
“Expanded RAS”
Presented By Alan Venook at 2014 ASCO Annual Meeting
<br /> Correlative Studies<br /> Tumor / Plasma / Serum > 44000 samples<br />
Presented By Alan Venook at 2014 ASCO Annual Meeting
80405: Upcoming Presentations
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Conclusions
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Conclusions
Presented By Alan Venook at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Conclusions
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 30
Presented By Alan Venook at 2014 ASCO Annual Meeting
TAKE HOME MESSAGE
Presented By Alan Venook at 2014 ASCO Annual Meeting
Value of publicly funded clinical research
Presented By Alan Venook at 2014 ASCO Annual Meeting
ACKNOWLEDGEMENTS / THANKS Collaborators
Presented By Alan Venook at 2014 ASCO Annual Meeting
ACKNOWLEDGEMENT / THANK YOU
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 35
Presented By Alan Venook at 2014 ASCO Annual Meeting
Slide 36
Presented By Alan Venook at 2014 ASCO Annual Meeting
